WAY
Waystar Holding Corp. · Healthcare · Medical - Healthcare Information Services
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 116.61M | $2.39B | +11 | −14 |
| Q1 2026 | 107 | -2 | 114.47M | $2.76B | +10 | −13 |
| Q4 2025 | 109 | -1 | 121.70M | $3.99B | +2 | −2 |
| Q3 2025 | 21 | +1 | 56.47M | $2.14B | +3 | −3 |
| Q2 2025 | 18 | 0 | 34.26M | $1.40B | — | — |
| Q1 2025 | 15 | +3 | 10.70M | $399.64M | +3 | — |
| Q4 2024 | 12 | +1 | 7.41M | $271.94M | +2 | −1 |
| Q3 2024 | 10 | +2 | 6.29M | $175.53M | +4 | −2 |
| Q2 2024 | 8 | — | 6.62M | $142.40M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 3.69M | — | $79.40M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.23M | — | $26.51M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Adage Capital Partners ✦ | 600.00K | — | $12.90M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 380.03K | — | $8.17M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 291.13K | — | $6.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Soros Fund Management ✦ | 250.00K | — | $5.38M | 0.2% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 138.11K | — | $2.97M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 37.80K | — | $812,700 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 303 holders, 203.38M shares, $4.82B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 82.50K sh · $2.16M
Officer, Director · 82.50K sh · $2.14M
Officer, Director · 60.04K sh · $1.50M
Officer, Director · 22.46K sh · $562,354
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology